Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 3,101–3,200 of 4,275
Rajesh, A., Havas, A. P., Arnold, R., Lande, K., Evensen, K. G., Li, K. Y., Mamde, S., Yang, Q., Gandhi, A., Miller, K. N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.01.668243 · Cited by 4
“To investigate how CCND1–CDK6 supports SASP and ISG expression in senescent cells, we tested whether it contributes to the accumulation of DNA damage and CCFs, precursors to SASP/ISG induction via cytosolic DNA signaling 11–18 .. Palbociclib significantly reduced DNA damage in IR-induced senescent IMR90s, as measured…”
InfluentialAging skin and non-surgical procedures: a basic science overview
Vandiver, A. R., & Hogan, S. R. (2020) · Plastic and Aesthetic Research · doi:10.20517/2347-9264.2020.159 · Cited by 10
“Despite stopping replication, they are metabolically active and have a distinct secretory profile known as the senescence-associated secretory phenotype (SASP) which can have profound effects on surrounding cells([79,80]).”
BackgroundFredoc-Louison, J., Cherrière, M., Rival, B., Araujo, S. D., François, S., & Dekali, S. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1722968 · Cited by 5
Krebs und Alter – biologische Grundlagen
von Figura, G., & Rudolph, K. L. (2009) · Onkologie · doi:10.1159/000228653 · Cited by 6
Sucularlı, C., Demir, Y. D. Ş., Özdemir, A., & Ark, M. (2024) · Biosystems · doi:10.1016/j.biosystems.2024.105140 · Cited by 4
Cigarette sidestream smoke-induced cellular senescence and the protective role of histone H2AX
Komaki, Y., & Ibuki, Y. (2025) · Toxicology in Vitro · doi:10.1016/j.tiv.2025.106076 · Cited by 4
IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis
Dema, M. G., Eixarch, H., Castillo, M., Montalbán, X., & Espejo, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126732 · Cited by 4
“…which is called “immunosenescence”, is associated to the production of a senescence-associated secretory phenotype (SASP), characterized by the production of proinflammatory cytokines, chemokines, growth factors and extracellular matrix proteases that create a senescent microenvironment [1].”
BackgroundHydrogen sulfide inhibits the rupture of fetal membranes throngh anti-aging pathways
Wang, J., Xu, J., Chao, B., Liu, H., Xie, L., Qi, H., & Luo, X. (2023) · Placenta · doi:10.1016/j.placenta.2023.09.006 · Cited by 4
Li, M., Liu, J.-X., Ma, B., Liu, J., Chen, J., Jin, F., Hu, C., Xu, H., Zheng, C., & Hou, R. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10710-w · Cited by 6
Hua, H., Zheng, C., Fan, J., Li, X., Xie, W., Chen, J., & Yu, C. (2022) · BioMed Research International · doi:10.1155/2022/1916787 · Cited by 3
“It exerts an indispensable function in tumor development by secretion of senescence-associated secretory phenotype (SASP) [29].”
Dynamic and scalable assessment of the senescence-associated secretory phenotype (SASP)
Malaquin, N., & Rodier, F. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.10.005 · Cited by 9
Self-citationComprehensive analysis of gene signatures associated with aging in human aortic dissection
Yan, J., & Tan, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31298 · Cited by 4
Lee, J., Oh, J., Kim, J. R., Ha, H., Kim, T., & Jeong, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157123 · Cited by 5
“These include pro-inflammatory cytokines [e.g., interleukin (IL)-1 α , IL-1 β , IL-6, and IL8], chemokines [e.g., C-C motif ligand 1 (CCL1), CCL2, and CCL5], proteases (e.g., matrix metalloprotease and serine protease), and growth factors (e.g., PDGF) [9,10].”
Lund, P. J., Lopes, M. D. C., Sidoli, S., Coradin, M., Vitorino, F. N. D. L., da Cunha, J. P. C., & Garcia, B. A. (2021) · Molecular Omics · doi:10.1039/d1mo00019e · Cited by 5
Damage-Free Shortening of Telomeres Is a Potential Strategy Supporting Blind Mole-Rat Longevity
Shekhidem, H. A., Sharvit, L. E., Huffman, D. M., Manov, I., Atzmon, G., & Shams, I. (2023) · Genes · doi:10.3390/genes14040845 · Cited by 5
Cellular senescence: mechanisms and clinical implications
Михайловна, М. А., Pashenkov, M. V., & Pinegin, B. V. (2024) · Immunologiya · doi:10.33029/1816-2134-2024-45-2-221-234 · Cited by 10
Shen, J., Hu, L., Huang, X., Mao, J., Wu, Y., Xie, Z., & Lan, Y. (2024) · Bone · doi:10.1016/j.bone.2024.117076 · Cited by 8
Türkoğlu, B., & Mansuroğlu, B. (2024) · Life · doi:10.3390/life14091070 · Cited by 10
“This phenotype includes many cytokines, chemokines, matrix metalloproteinases, and other proteins [21–23].”
BackgroundImmunosenescence and Cancer Immunotherapy at Old Age: Basics
Fülöp, T., Witkowski, J. M., Hirokawa, K., Larbi, A., & Pawelec, G. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_77 · Cited by 5
A Human Embryonic Stem Cell-derived Neural Stem Cell Senescence Model Triggered by Oxidative Stress
Pan, H., Li, B., Ji, M., Lyu, Z., Qi, N., & Wu, Y. (2025) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x365639250214045110 · Cited by 4
Yu, X., Lobo, J. D., Sundermann, E. E., Baker, D. J., Tracy, R. P., Kuchel, G. A., Stephenson, K. E., Letendre, S. L., Brew, B. J., Cysique, L. A., et al. (2022) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2022.0079 · Cited by 6
“Senescent cells, which are stably growth arrested and produce a bioactive secretome, 8 arise in response to a variety of intrinsic and extrinsic stresses, including extended passage in culture, telomere attrition/ damage, excessive oncogene activation, tumor suppressor loss, proteotoxic damage, and…”
Analysis of somatic mutations in senescent cells using single-cell whole-genome sequencingPreprint
Zhang, L., Cecco, M. D., Lee, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.16.508266 · Cited by 4
Self-citationSingle-cell atlas of the human immune system reveals sex-specific dynamics of immunosenescencePreprint
Sopena-Rios, M., Ripoll-Cladellas, A., Omidi, F., Ballouz, S., Alquicira-Hernández, J., Oelen, R., Franke, L., van der Wijst, M. G. P., Powell, J. E., & Melé, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.06.622096 · Cited by 4
“As the immune system regulates infection, tissue repair, inflammation, and cancer surveillance, its dysfunction contributes to organism-wide aging 126–128 .”
Common Challenges in Tissue Regeneration
Eriksson, J., D’Angelo, W., & Badylak, S. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814879-2.00009-1 · Cited by 4
Gaspary, J. F. P., Lopes, L. F. D., Gaspary, F. P., Lopes, E. G., Edgar, A. L., Camara, E. P., & Camara, A. G. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1824897 · Cited by 4
“Cellular senescence is characterized not only by cell-cycle arrest but by sustained secretion of pro-inflammatory cytokines, growth factors, matrix-remodeling enzymes, and redox-active mediators that reshape the surrounding microenvironment (60, 61).”
Sohn, J., Jeon, M., Lee, H., Lim, J., Ham, S., Park, J., Lee, J., Jung, Y., Lee, G., Min, H., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.04.030 · Cited by 4
The Molecular Interplay Between p53-Mediated Ferroptosis and Non-Coding RNAs in Cancer
Punziano, C., Trombetti, S., Grosso, M., Tornesello, M. L., & Faraonio, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146588 · Cited by 5
RGL2 as an age-dependent factor regulates colon cancer progression
Cheng, Q., Wu, Y., Xia, H., & Song, X. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.006 · Cited by 5
“and tumorigenesis through senescence-associated secretory phenotypes in a proinflammatory context [13,14].”
BackgroundDing, L., Wang, X., Liu, Q., Zhang, Y., Wu, X., Xiao, B., Liu, D., Chen, L., Zeng, H., Zhao, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01442 · Cited by 4
Proceedings of the inaugural Dark Genome Symposium: November 2022
Boeke, J. D., Burns, K. H., Chiappinelli, K. B., Classon, M., Coffin, J. M., DeCarvalho, D., Dukes, J. D., Greenbaum, B. D., Kassiotis, G., Knutson, S. K., et al. (2023) · Mobile DNA · doi:10.1186/s13100-023-00306-5 · Cited by 3
Yu, S., Ye, J., Wang, Y., Lu, T., Liu, Y., Liu, N., Zhang, J., Lu, F., Ma, D., Gale, R. P., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102787 · Cited by 5
hTERT Increases TRF2 to Induce Telomere Compaction and Extend Cell Replicative Lifespan
Adam, N., Yang, Y., Djamshidi, M., Seifan, S., Ting, N. S. Y., Glover, J., Touret, N., Gordon, P. M. K., Warriyar, K. V. V., Krowicki, H., et al. (2025) · Aging Cell · doi:10.1111/acel.70105 · Cited by 4
“This is consistent with previous observations indicating that WT hTERT can enhance DNA repair and reduce spontaneous chromosome damage (Sharma et al. 2003) and inhibit TP53 activation and DNA damage signaling (Beliveau and Yaswen 2007).”
InfluentialBoroumand, M., Dey, A. K., Cupp‐Sutton, K. A., Pierce, T., Tsitsipatis, D., Herman, A. B., Wu, S., & Basisty, N. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c02694 · Cited by 6
Mutations in foregut SOX2+ cells induce efficient proliferation via CXCR2 pathway
Hishida, T., Vazquez-Ferrer, E., Hishida, Y., Sancho-Martinez, I., Takahashi, Y., Hatanaka, F., Wu, J., Ocampo, A., Reddy, P., Wu, M.-Z., et al. (2019) · Protein & Cell · doi:10.1007/s13238-019-0630-3 · Cited by 6
Stem cell-based therapeutic strategies for liver aging
Niu, H., Wang, Y., Ding, Y. S., Lin, Y., Qin, J., & Wang, J. (2025) · Liver Research · doi:10.1016/j.livres.2025.04.003 · Cited by 5
The cGAS–STING pathway in cancer immunotherapy: prognostic value and therapeutic potential
Alabi, F. A., Imodoye, S. O., Adedokun, K. A., Eltokhy, M. A., Curcic, M., Okoyeocha, E., Thapa, I., Tiwari, S., Ogundele, A. V., Ayo, T. E., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1760947 · Cited by 7
He, Y., Long, K., Du, B., Liao, W., Zou, R., Su, J., Luo, J., Shi, Z., & Wang, L. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150576 · Cited by 7
Pei, Z., Liang, F., Wang, X., & Li, H. (2026) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2026.112174 · Cited by 8
Lefebvre, C. C., Giowachini, P., Derrien, J., Naour, M., Corre, I., Thirouard, L., Douillard, E., Chiron, D., Guillonneau, F., Treps, L., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07920-6 · Cited by 6
“It is relevant to note here that prior reports have described MCL-1 as an inhibitor of chemotherapy-induced senescence across various models [37, 38] and that chemotherapy induces in some cell types a senescence-associated secretory phenotype which includes pro-angiogenic factors [39, 40].”
Two-stage model of carcinogenic mutations with the influence of delays
Foryś, U., & Jackowska-Zduniak, B. (2014) · Discrete and Continuous Dynamical Systems - B · doi:10.3934/dcdsb.2014.19.2501 · Cited by 4
Loss of CFTR Reverses Senescence Hallmarks in SARS-CoV-2 Infected Bronchial Epithelial Cells
Merigo, F., Lagni, A., Boschi, F., Bernardi, P., Conti, A., Plebani, R., Romano, M., Sorio, C., Lotti, V., & Sbarbati, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116185 · Cited by 4
Decoding senescent drivers in Alzheimer's disease: From bench to bedside
Zhou, R., Lin, X., Liao, Z., Lin, J., Zheng, R., Ni, H., Liu, W., Feng, Z., He, Q., Lin, X., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102978 · Cited by 4
Screening Method for Identifying Toxicants Capable of Inducing Astrocyte Senescence
Woods, G., & Andersen, J. K. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy181 · Cited by 4
Nishimura, J., Morita, Y., Tobe‐Nishimoto, A., Kitahira, Y., Takayama, S., Kishimoto, S., Matsumiya, Y., Takeshita, A., Matsunaga, K., Imai, T., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112377 · Cited by 4
Shboul, S. A., Karsaneh, O. A. A., Alrjoub, M., Alqudah, M. A. Y., El‐Sadoni, M., Alhesa, A., Ramadan, M., Barukba, M., Al-Quran, E. F., Masaadeh, A. H., et al. (2025) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320251324821 · Cited by 4
Extension of Life Span in Laboratory Mice
Unnikrishnan, A., Deepa, S. S., Herd, H. R., & Richardson, A. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00019-1 · Cited by 8
Barinda, A. J., Arozal, W., & Yuasa, S. (2022) · Medical Journal of Indonesia · doi:10.13181/mji.rev.226064 · Cited by 4
The Human Ovary Exhibits Dynamic Molecular Remodeling in the Decades Post‐Menopause
Watson, M. A., Soygur, B., King, C. D., Devrukhkar, P. R., Melov, S., Shanes, E. D., Pavone, M. E., Duncan, F. E., & Schilling, B. (2026) · Aging Cell · doi:10.64898/2026.03.26.714635 · Cited by 5
“These changes relate to extracellular remodeling, metabolic stress responses, and innate immune signaling, characteristic of the senescence-associated secretory phenotype (SASP) (Basisty et al., 2020; Coppe et al., 2008).”
Iswarya, B. R., & John, C. M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10904-6 · Cited by 5
A regulatory biomimetic nanoparticle targeting senescent glioma cells for BNCT treatment
Dai, Q., Zhang, Z., Ben, Z., Sun, X., Yang, Y., Qin, Y., Yang, Q., Bao, X., Wu, L., Jiang, R., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.174453 · Cited by 4
Therapeutic Senolysis of Axitinib-Induced Senescent Human Lung Cancer Cells
Kotani, H., Han, W., Iida, Y., Tanino, R., Katakawa, K., Okimoto, T., Tsubata, Y., Isobe, T., & Harada, M. (2024) · Cancers · doi:10.3390/cancers16162782 · Cited by 5
Deacceleration of Brain Aging by Melatonin
Hardeland, R. (2016) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-319-33486-8_18 · Cited by 4
Zhang, Y., Ren, X., Zhuang, H., Li, H., Adam, M. S., Feng, R., Zhu, J., & Zhou, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325704 · Cited by 4
Kobayashi, H., Shigetomi, H., Nishio, M., Umetani, M., Imanaka, S., & Hashimoto, H. (2025) · Reproductive Sciences · doi:10.1007/s43032-025-01970-z · Cited by 5
“The cytokines and growth factors secreted as part of SASP can also promote epithelial–mesenchymal transition (EMT) and invasive properties in neighboring precancerous cells, thereby acting as pro-tumorigenic factors [157, 159] (Zone 2 in Fig.”
From Genome Guardian to Immune Modulator: The Expanding Roles of Tumor Suppressor p53
Wang, W., Liu, J., Feng, Z., & Hu, W. (2025) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2571187 · Cited by 4
“14,15 Accumulating evidence has indicated that p53 is also a critical player in many processes related to immune function.”
Molecular mechanisms of cellular senescence
Nehme, J., Varela-Eirín, M., & Demaria, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823318-4.00034-2 · Cited by 4
Santos‐Sousa, D., da Rosa, S., & Filippi‐Chiela, E. C. (2025) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2025.112052 · Cited by 9
Immunosenescence and Cancer Immunotherapy at Old Age: Basics
Fülöp, T., Witkowski, J. M., Hirokawa, K., Larbi, A., & Pawelec, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-44870-1_77-1 · Cited by 4
The role of cellular senescence in wound healing of diabetic skin
Ueda, N., Saito, Y., Ota, K., Nagao, A., Kasseki, D., & Chikenji, T. (2026) · The Journal of Biochemistry · doi:10.1093/jb/mvag006 · Cited by 5
Muda, M. (2011) · Cell Cycle · doi:10.4161/cc.10.17.16574 · Cited by 4
de Mendonça, L. B., Lenz, G., & Filippi‐Chiela, E. C. (2025) · Biochemical Society Transactions · doi:10.1042/bst20253054 · Cited by 5
“The main transcription factors controlling the expression of SASP-associated genes are NF-κB [87], CCAAT/enhancer binding protein beta (C/EBPβ) [88], neurogenic locus notch homolog protein 1 (NOTCH1) [109], GATA4 [110], Proto-oncogene MYB (c-Myb) [88], and TP53 [3].”
Srour, E., Martin, N., Drullion, C., de Schutter, C., Giroud, J., Pioger, A., Deslé, J., Saas, L., Nassour, J., Théry, J., et al. (2024) · Aging · doi:10.18632/aging.206149 · Cited by 7
Dyskeratosis Congenita Links Telomere Attrition to Age-Related Systemic Energetics
James, E. N., Sági‐Kiss, V., Bennett, M. H., Mycielska, M. E., Karen‐Ng, L. P., Roberts, T., Matta, S., Dokal, I. S., Bundy, J. G., & Parkinson, E. K. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad018 · Cited by 5
“Telomere dysfunction culminates in cellular senescence, which is accompanied by the accumulation of an array of extracellular proteins and metabolites, known as the senescence-associated secretory phenotype (SASP (17)) and the extracellular senescence metabolome (ESM (18)), respectively.”
BackgroundStem Cell Senescence as the Memory of Past Injuries
Gianfranceschi, G., Gri, G., Cesselli, D., & Beltrami, A. P. (2015) · Current Pathobiology Reports · doi:10.1007/s40139-015-0071-5 · Cited by 5
“Moreover, the SASP composition could depend on type of mechanism triggering the senescence process and may vary with time [65, 66].”
BackgroundA strategy for the treatment of gastrointestinal cancer: Targeting tumor senescent cells
Liu, Y., Zhang, Q., Ni, W., Ji, G., & Xu, H. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1139840 · Cited by 4
“Studies have shown that senescent cells release SASP factors such as IL-6 and IL-8 into the tumor microenvironment, which can induce epithelial-mesenchymal transformation and thus play a role in promoting metastasis and invasion (Coppe et al., 2008).”
BackgroundWang, M., Han, Y., Yao, X., Duan, X., Wan, J., Lou, X., Yan, Y., Zheng, P., Wang, F., Zhu, L., et al. (2024) · MedComm · doi:10.1002/mco2.605 · Cited by 6
“3,9,10 However, the key intrinsic pathways, especially the TNF-α receptors, regulating MDSCs’ differentiation during ageing are elusive.”
BackgroundPredicting lung aging using scRNA-Seq data
Song, Q., Singh, A., McDonough, J. E., Adams, T. S., Vos, R., Man, R. D., Myers, G., Ceulemans, L. J., Vanaudenaerde, B. M., Wuyts, W. A., et al. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012632 · Cited by 5
Antonangeli, F., Arcuri, E., & Santoni, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1694567 · Cited by 4
Cellular Senescence in Diffuse Gliomas: From Physiopathology to Possible Treatments
Ordóñez-Rubiano, E. G., Cómbita, A. L., Baldoncini, M., Payán‐Gómez, C., Gómez-Amarillo, D. F., Hakim, F., Camargo, J., Zorro-Sepúlveda, V., Luzzi, S., Zorro, Ó., et al. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.08.060 · Cited by 6
Exploring age-related influences on COVID-19 severity and therapeutic approaches for older patients
Hossain, S., Islam, S., Kamruzzaman, M., & Shekhar, H. U. (2025) · Aging and Health Research · doi:10.1016/j.ahr.2025.100259 · Cited by 8
Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells
Tchelougou, D., Malaquin, N., Cardin, G. B., Desmul, J., Turcotte, S., & Rodier, F. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1368711 · Cited by 6
Self-citationMurthy, S., Seabold, D., Gautam, L. K., Caceres, A. M., Sease, R., Calvert, B. A., Busch, S. M., Neely, A., Marconett, C. N., & Ryan, A. L. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00293.2024 · Cited by 6
Lai, S., Lin, C.-Y., Li, L., Qiu, W., Zhang, J., & Guo, T. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s575832 · Cited by 3
Guilatco, A. J., Shah, M. V., & Weivoda, M. M. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100620 · Cited by 5
N-cadherin in osteolineage cells modulates stromal support of tumor growth
Fontana, F., Xiang, J., Su, X., Tycksen, E., Nassau, R., Fox, G. C., Leanza, G., Weilbaecher, K. N., & Civitelli, R. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100356 · Cited by 3
Cellular Senescence and Tumor Promotion
Demaria, M. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_79 · Cited by 4
Effect of daikenchuto (TU-100) on carcinogenesis in non-alcoholic steatohepatitis
Yamada, S., Morine, Y., Imura, S., Ikemoto, T., Saito, Y., Ichimura‐Shimizu, M., Tsuneyama, K., Nishiyama, M., Ishizawa, S., & Shimada, M. (2023) · The Journal of Medical Investigation · doi:10.2152/jmi.70.66 · Cited by 3
Endometrial cellular senescence contributes to preterm birth
Hirota, Y. (2014) · Inflammation and Regeneration · doi:10.2492/inflammregen.34.064 · Cited by 3
The transformative promise of aging science
Stipp, D. (2012) · Cell Cycle · doi:10.4161/cc.22211 · Cited by 4
Li, Z., Li, J., Zhang, L., Zhang, L., Zhou, H.-R., Bai, Y., Lv, J., Deng, Z.-Y., & Liu, C. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20433 · Cited by 3
“On the one hand, chronic inflammatory mediators produced by senescent cells induce epithelial-mesenchymal transition and stimulate the proliferation of malignant epithelial cells (13).”
BackgroundA novel role of Fas in delaying cellular senescence
Saha, C., Li, J., Sun, X., Liu, X., & Huang, G. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13451 · Cited by 4
“These cells show irreversible cell cycle arrest in combination with metabolic and epigenomic changes including senescence-associated SA-β-gal positivity, the senescence-associated secretory phenotype (SASP) [6] and senescence-associated heterochromatin formation (SAHF).”
BackgroundUnraveling senescence in cancer: mechanistic complexities and therapeutic opportunities
Tiwari, P., Shukla, S. K., & Verma, S. R. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10630-z · Cited by 5
Andersen, J. K., & Chinta, S. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_8 · Cited by 5
Telomeres and Cellular Senescence in Metabolic and Endocrine Diseases
Matsumoto, R., & Takahashi, Y. (2016) · InTech eBooks · doi:10.5772/64759 · Cited by 5
“Although whether the SASP actually causes age-related diseases including metabolic diseases in vivo is still unclear, at least, telomere shortening and subse‐ quent cellular senescence have revealed a strong association with age-related diseases including metabolic diseases that are discussed in the following sections.”
BackgroundInfluentialPicallos-Rabina, P., Silva‐Álvarez, S. D., Antelo-Iglesias, L., Triana-Martínez, F., & Collado, M. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-44903-2_5 · Cited by 3
Hom, L. M., Sun, S., Campbell, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.21.529458 · Cited by 3
A bibliometric study of the top 100 most cited papers on aging and cancer
Zhang, Y., Guo, Y., & Zhang, C. (2023) · Medicine · doi:10.1097/md.0000000000034428 · Cited by 9
“In normal cells, oncogenic RAS expression leads to genotoxic stress and senescence, thus promoting the development of age-related cancer (T35).[18] From the angle of DNA methylation levels, it played a role as a biologically meaningful predictor of the cumulative effect of an epigenetic maintenance system and provided…”
BackgroundWijayasiri, P., Astbury, S., Needham, G., Kaye, P., Bhat, M., Piccinini, A. M., & Aravinthan, A. D. (2025) · Human Cell · doi:10.1007/s13577-025-01201-2 · Cited by 5
“IL-6 and IL8, secreted by senescent fibroblasts in breast cancer, drive epithelial-to-mesenchymal transition in cancer cells and enhance the invasiveness of multiple cultured cancer cell lines [38].”
Inoue, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802005-0.00043-4 · Cited by 4
González, I., Arredondo, S. B., & Maldonado‐Agurto, R. (2025) · Biogerontology · doi:10.1007/s10522-025-10191-5 · Cited by 3
“Despite losing their ability to proliferate, senescent cells remain metabolically active and secrete a wide range of pro-inflammatory cytokines, chemokines, growth factors, and metalloproteases, collectively known as the senescence-associated secretory phenotype (SASP) (Coppé et al. 2008).”
InfluentialWang, B., Piccolantonio, A., Altulea, A., Huang, M., Joshi, T., Pagliarin, F., Palma, M. D., Lin, Y., Mackedenski, S. J., Ustyantsev, K., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01168-1 · Cited by 5
“1h), in support of the p53-suppressing role on the pro-inflammatory SASP previously described 2,23 .”
Tang, X., Hu, J., Fan, X., Su, H., Li, M., Zhang, L., & Ma, D. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00541-9 · Cited by 4
“These molecules modulate the cellular microenvironment and intercellular communication [60], while also serving as potential biomarkers of senescence [61].”
Han, J. S., Wang, J., Shen, L., Cai, Y., Wang, X., Wumaier, A., Chen, W., & Han, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1534120 · Cited by 4
Koll, T. T., Magnuson, A. M., Dale, W., LaBarge, M. A., Leach, C. R., Mohile, S. G., Muss, H. B., Sedenquist, M., & Klepin, H. D. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.09.006 · Cited by 4
Wang, Z., Wu, X., Dai, Q., Liu, Z., Zhao, C., Wei, L. T., Zhao, Y., Li, L., & Wang, X. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103666 · Cited by 4
Premature Rupture of Membranes (PROM)
Navti, O. B. (2021) · Springer eBooks · doi:10.1007/978-3-030-75385-6_13 · Cited by 6
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.